About the Journal
Journal of Anaesthesiology Clinical Pharmacology is a quarterly peer-reviewed international journal, and is an official publication of the Research Society of Anaesthesiology Clinical Pharmacology. The
journal’s full text is available online at www.joacp.org. The journal allows free access (Open Access) to its contents and permits authors to self-archive final accepted version of the articles on any OAI-compliant
institutional / subject-based repository. The journal does not charge for submission, processing or publication of manuscripts and even for color reproduction of photographs. The journal follows the ICMJE guidelines
and is member of WAME, and COPE. The journal is indexed with various international indexing agencies including Pubmed, Pubmed central, and SCOPUS.
Abstracting and Indexing Information
The journal is indexed with Caspur, CNKI (China National Knowledge
Infrastructure), EBSCO Publishing's Electronic Databases, Expanded
Academic ASAP, Genamics JournalSeek, Global Health, Google Scholar,
Health & Wellness Research Center, Health Reference Center Academic,
Hinari, Index Copernicus, Indian Science Abstracts, MANTIS, National
Science Library, OpenJGate, PrimoCentral, ProQuest, PubMed, Pubmed
Central, SafetyLit, Scimago Journal Ranking, SCOLOAR, SCOPUS, SIIC
databases, Summon by Serial Solutions and Ulrich's International Periodical
Scope of the journal
The journal covers clinical and technical studies related to Anesthesiology and
publishes original peer-reviewed research and clinical work in Anesthesiology, Pain,
Critical Care, Perioperative Medicine and all specialties of anesthesia including
translational aspects of basic science research, equipment, training and ethics. Articles
of high impact clinical research and those with implications for clinical practice
will be given preference. The journal also publishes commissioned review articles,
commentaries, and editorials alongwith clinically relevant novel case reports/series,
correspondence and special articles of general interest.
The Editorial Process
A manuscript will be reviewed for possible publication with the understanding and
written undertaking that it is being submitted to Journal of Anaesthesiology Clinical
Pharmacology alone at that point in time and has not been published anywhere,
simultaneously submitted, or already accepted for publication elsewhere. Only
manuscripts containing original material will be considered for publication. The
journal expects that authors would authorize one of them to correspond with the
Journal for all matters related to the manuscript. All manuscripts received are duly
acknowledged. On submission, editors review all submitted manuscripts initially
for suitability for formal review. Manuscripts with insufficient originality, serious
scientific or technical flaws, or lack of a significant message are rejected before
proceeding for formal peer-review. Manuscripts that are unlikely to be of interest to
the Journal of Anaesthesiology Clinical Pharmacology readers are also liable to be
rejected at this stage itself.
Manuscripts that are found suitable for publication in Journal of Anaesthesiology
Clinical Pharmacology are sent to three or more expert reviewers. During
submission, the contributor is requested to provide names of two or three qualified
reviewers who have had experience in the subject of the submitted manuscript,
but this is not mandatory. The reviewers should not be affiliated with the same
institutes as the contributor/s. However, the selection of these reviewers is at the
sole discretion of the editor. The journal follows a double-blind review process,
wherein the reviewers and authors are unaware of each other’s identity. Every
manuscript is also assigned to a member of the editorial team, who based on
the comments from the reviewers takes a final decision on the manuscript. The
comments and suggestions (acceptance/ rejection/ amendments in manuscript)
received from reviewers are conveyed to the corresponding author. If required, the
author is requested to provide a point by point response to reviewers’ comments and submit a revised version of the manuscript. This process is repeated till
reviewers and editors are satisfied with the manuscript. The Chief Editor’s
verdict on acceptance or rejection is final.
Manuscripts accepted for publication are copy edited for grammar, punctuation,
print style, and format. Page proofs are sent to the corresponding author. The
corresponding author is expected to return the corrected proofs within two days.
It may not be possible to incorporate corrections received after that period. The
whole process of submission of the manuscript to final decision and sending and
receiving proofs is completed online. To achieve faster and greater dissemination of
knowledge and information, the journal publishes articles online as ‘Ahead of Print’
immediately on acceptance.
Journal of Anaesthesiology Clinical Pharmacology (JOACP) follows the
recommendations of International Committee of Medical Journal Editors (ICMJE);
the authorship credit should be based on:
- Substantial contribution to conception and design, acquisition of data, or
analysis and interpretation of data;
- Drafting the article or revising it critically for important intellectual content;
- Final approval of the version to be published; and
- Agreement to be accountable for all aspects of the work thereby ensuring
that questions related to the accuracy or integrity of any part of the work are
appropriately investigated and resolved.
All authors should meet all four conditions to comply with ICMJE
All persons or institutions involved in the conduct of the work must be mentioned
in the authors list or acknowledged. Contributions of each author to the research
and /or manuscript should be outlined on the title page of all manuscripts submitted
to JOACP. Ghostwritten papers are discouraged by the journal. Participation
solely in the acquisition of funding or the collection of data does not justify
authorship. General supervision of the research group is not sufficient for authorship.
Each contributor should have participated sufficiently in the work to take public
responsibility for appropriate portions of the content of the manuscript. The order of
naming the contributors should be based on the relative contribution of the contributor
towards the study and writing the manuscript. Once submitted the order cannot be
changed nor the names changed without written consent of all the contributors. The
journal prescribes a maximum number of authors for manuscripts depending upon
the type of manuscript, its scope and number of institutions involved (vide infra).
The authors should provide a justification, if the number of authors exceeds these
limits. One or more author should take responsibility for the integrity of the work as
a whole from inception to published article and should be designated as ‘guarantor’.
Duplicate or part publication
The authors should not submit the manuscript that has been submitted somewhere
else or published previously in full or in part in any form. This may not apply to
publication of manuscript as abstract in scientific proceedings but it must be mentioned
and acknowledged in the manuscript for the same. The journal strongly discourages
duplicate submission, and salami slicing of a single paper and its data collection
into multiple papers for publication. In case any further clarification is required on
this specific issue, please contact the Editor-in-Chief.
All human trials must be conducted and reported as per ethical standards and must
be approved by appropriate authorities including Institutional Review Board (IRB)
and Ethical committee approval. It should also conform to the WMA declaration
of Helsinki on ethical principles for medical research involving human subjects.
The IRB, ethical committee approval number and consent procedures needs to be
mentioned in the method section. Absence of appropriate approvals, consent for
study and publication and documentation may be a reason for outright rejection of the
manuscripts. If consent has been waived by competent authority or ethical committee,
it needs to be explicitly mentioned. The name of ethical committee and IRB
alongwith IRB approval number needs to be mentioned in the Title
page. It includes the chairperson or member secretary’s name, approval
number with date, and Institute’s name. The ethical committee approval
letter needs to be submitted as additional material during the submission.
The investigational drug used in the study needs to be as per approval from the
relevant country’s drug authority approval. In case, a drug is being used ‘off label’,
then approval from competent authority needs to be taken and must be discussed in
the discussion section regarding its non approval for routine use.
Case Reports/Case Series: Written patient consent or guardian/parent consent
in cases of minor must be taken for publication and mentioned in the manuscript.
Consent for publication shall be required to be submitted prior to proceeding with
the review process for the case report.
Registration of clinical trials with registry
The journal suggests that all the clinical trials should be registered with clinical
registry before the start of the patient recruitment for the study. Authors are requested
to provide the exact URL of the registry, and unique identification number for the
trial registration, principal investigator’s name, and date of registration at the time
of submission and this would be published in the article beneath the key words.
This information should be included on the title page at the time of submission
and not in the article file.
In accordance with the ICMJE’s recommendation, JOACP will also accept registration
of clinical trials in any of the primary registers that participate in the World Health
Organization’s International Clinical Trial Registry Platform. The Clinical Trials
Registry- India (CTRI), is one of the primary registry of WHO’s international
Clinical trial registry platform. It is hosted at the ICMR’s National Institute of
Medical Statistics (http://nims-icmr.nic.in), is free and online public record system for
registration of clinical trials being conducted in India (www.ctri.nic.in). Initiated as a
voluntary measure, since 15th June 2009, trial registration in the CTRI has been made
mandatory by the Drugs Controller General (India) (DCGI) (www.cdsco.nic.in).
Clinical trial reports should also comply with the Consolidated Standards of
Reporting Trials (CONSORT) and include a flow diagram presenting the
enrollment, intervention allocation, follow-up, and data analysis with number of
subjects for each. Please also refer specifically to the CONSORT Checklist of items
to include when reporting a randomized clinical trial.
Journal of Anaesthesiology Clinical Pharmacology reserves the right to use plagiarism
detection software on any submitted material at any time and reject the article at any
stage on detection of plagiarism.
Conflicts of Interest/ Competing Interests
The conflict of interest in all sorts (personal, professional or business affiliation
relevant to the paper) must be disclosed by all the authors during the submission of
the manuscript to the journal. The source of funding for the clinical work or funding to
the authors otherwise needs to be mentioned. The commercial interest of the authors
must be mentioned in the manuscript.
Submission of Manuscripts
All manuscripts must be submitted on-line through the website www.journalonweb.com/jacp. First time users will have to register at this site.
Registration is free but mandatory. Registered authors can keep track of their articles after logging into the site using their user name and password. Authors do not have to pay for submission, processing or publication
of articles. If you experience any problems, please contact the editorial office by e-mail at editorjoacp @ gmail . com.
The original article must be submitted along with the consort checklist that may be
downloaded from the link: www.consort-statement.org. The other link of Consort flow
diagram and checklist that needs to be submitted along with submisision of the original
article is http://www.consort-statement.org/consort-statement/overview0/#checklist
The submitted manuscripts that are not as per the “Instructions to Authors” would be returned to the authors for technical correction, before they undergo editorial/ peer-review. Generally,
the manuscript should be submitted in the form of two separate files:
 Title Page/First Page File/covering letter:
This file should provide
The type of manuscript (editorial, original article, case report, review article, brief communication, and letter to editor) title of the manuscript, running title, names of all authors/ contributors (with
their highest academic degrees, designation and affiliations) and name(s) of department(s) and/ or institution(s) to which the work should be credited. All information which can reveal your identity should be here.
Use text/rtf/doc files. Do not zip the files.
Source(s) of support in the form of grants, equipment, drugs, or all of these;
Acknowledgement, if any. One or more statements should specify 1) contributions that need acknowledging but do not justify authorship, such as general support by a departmental chair; 2)
acknowledgments of technical help; and 3) acknowledgments of financial and material support, which should specify the nature of the support. This should be included in the title page of the manuscript and not in the
main article file.
If the manuscript was presented as part at a meeting, the organization, place, and exact date on which it was read. A full statement to the editor about all submissions and previous reports that
might be regarded as redundant publication of the same or very similar work. Any such work should be referred to specifically, and referenced in the new paper. Copies of such material should be included with the
submitted paper, to help the editor decide how to handle the matter.
Conflicts of Interest of each author/ contributor. A statement of financial or other relationships that might lead to a conflict of interest, if that information is not included in the manuscript itself or
in an authors' form
A statement that the manuscript has been read and approved by all the authors, that the requirements for authorship as stated earlier in this document have been met, and that each author
believes that the manuscript represents honest work, if that information is not provided in another form (see below); and
The name, address, e-mail, and telephone number of the corresponding author, who is responsible for communicating with the other authors about revisions and final approval of the proofs.
For original article: Ethical committee approval Chairperson
Name, Institute from where approval taken, date and Ethical
approval number needs to be mentioned along with the CTRI
unique ID and URL of the clinical trials registry where it has
been submitted prior to start of the trial on the Title page file.
Consent: Patient’s, Parent’s / guardian’s consent (in case of minor) in
case of case reports needs to be mentioned. Also, if any photographs
is to be published, consent for the same also needs to be taken and
mentioned in the tile page. (Vide above in consent section)
 Blinded Article file: The manuscript must not contain any mention of the authors' names or initials or the institution at which the study was done or acknowledgements. Page headers/running
title can include the title but not the authors' names. Manuscripts not in compliance with The Journal's blinding policy will be returned to the corresponding author. The main text of the article, beginning
from Abstract till References (including tables) should be in this file. Use rtf/doc files. Do not zip the files. Limit the file size to 1024 kb (1 MB). Do not incorporate images in the file. The pages should be numbered
consecutively, beginning with the first page of the blinded article file.
 Images: Submit good quality color images. Each image should be less than 4 MB in size. Size of the image can be reduced by decreasing the actual height and width of the images (keep up to
1800 x 1200 pixels or 5-6 inches). Images can be submitted as jpeg files. Do not zip the files. Legends for the figures/images should be included at the end of the article file.
 The contributors' / copyright transfer form (template provided below) has to be submitted in original with the signatures of all the contributors within two weeks of submission via courier,
fax or email (copyright @ medknow . com) as a scanned image. High resolution images (up to 5 MB each) can be sent by email on images @ medknow . com).
The hard copies of the Contributors’ form / copyright transfer form may be sent to the following addresses or submitted online from the authors’ area on www.journalonweb.com/joacp.
Dayanand Medical College and Hospital, Ludhiana
Preparation of Manuscripts
Manuscripts must be prepared in accordance with "Uniform requirements for Manuscripts submitted to Biomedical Journals" developed by the International Committee of Medical Journal
Editors (October 2006). The uniform requirements and specific requirement of Journal of Anaesthesiology Clinical Pharmacology are summarized below. Before submitting a manuscript, contributors are requested to
check for the latest instructions available. Instructions are also available from the website of the journal (http://www.joacp.org) and the manuscript submission site (http://www.journalonweb.com/joacp)
Journal of Anaesthesiology Clinical Pharmacology accepts manuscripts written in American English.
Copies of any permission(s)
It is the responsibility of authors/ contributors to obtain permissions for reproducing any copyrighted material. A copy of the permission obtained must accompany the manuscript. Copies of any and all
published articles or other manuscripts in preparation or submitted elsewhere that are related to the manuscript must also accompany the manuscript. The material should be sent to any of the two addresses given
Types of Manuscripts
The words limit needs to be adhered before submission. The total words do not
include title page, abstract, references, tables and figure legends.
Editorials -> 1500 words and 15 references
Original Article -> 3000 words and 30 references
Review Articles -> 3000 words and 90 references
Case Reports/Case Series -> 1000 words and 10 references
Letters to the Editor -> 500 words and 5 references
These include randomized controlled trials, intervention studies, studies of screening
and diagnostic test, outcome studies, cost effectiveness analyses, case-control series,
and surveys with high response rate. Audits or surveys needs to have some outcome
which may be applicable to other institutions as well or add some new information
in general. The text of original articles amounting to up to 3000 words (excluding
Abstract, references and Tables) should be divided into sections with the headings
Abstract & Key-words, Introduction, Material and Methods, Results, Discussion,
References, Tables and Figure legends.
Abstract & Key-words:
The page should have an abstract, in a structured format (Background; Methods;
Results; and Conclusions) for all original research articles in up to 250 words.
References are not to be used in this section. The abstract should state the purposes
of the study or investigation (Background); methods (study subjects or experimental
animals; observational and analytic methods); main findings or results (give specific
data and their statistical significance); and the principal conclusions. Three to 10
Key (indexing) words should be provided below the abstract. Provide keywords that
will assist indexers in cross indexing the article. Use terms from the medical subject
heading (MeSH) list of Index Medicus.
Introduction: States the purpose and summarizes the rationale or need for the study or observation.
The hypothesis of the study should specifically be mentioned. Introduction should
refer to the brief concise, background relevant to the subject in question for the study,
the lacunae in literature on the hypothesis and then state the hypothesis with the aims
of your study. The final paragraph should clearly state the primary and, if applicable,
secondary aims or outcomes of the study.
Materials and Methods: The Methods section should give a clear but concise description of the process of
the study. It should include and describe the following aspects:
- Ethics approval & Clinical Trial registry approval
- Patient population
- Inclusion / exclusion criteria
- Conduct of the study
- Data handling
Ethics:When reporting studies on human beings, indicate whether the procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation
(institutional or regional) and with the Helsinki Declaration of 1975, as revised in 2000 (available at http://www.wma.net/e/policy/17-c_e.html). For
prospective studies involving human participants, authors are expected to mention about approval of (regional/ national/ institutional or independent Ethics Committee or Review Board, obtaining informed consent
from adult research participants and obtaining assent for children aged over 7 years participating in the trial. The age beyond which assent would be required could vary as per regional and/ or national guidelines.
Ensure confidentiality of subjects by desisting from mentioning participants’ names, initials or hospital numbers, especially in illustrative material. When reporting experiments on animals, indicate whether the
institution’s or a national research council’s guide for, or any national law on the care and use of laboratory animals was followed.
Evidence for approval by a local Ethics Committee (for both human as well as
animal studies) must be submitted as scanned copy during submission and its
references needs to be quoted on the title page. Animal experimental procedures
should be as humane as possible and the details of anesthetics and analgesics
used should be clearly stated. The ethical standards of experiments must be in
accordance with the guidelines provided by the CPCSEA and World Medical
Association Declaration of Helsinki on Ethical Principles for Medical Research
Involving Humans for studies involving experimental animals and human
beings, respectively). Authors are advised to refer to the ARRIVE (Animals
in Research: Reporting In Vivo Experiments) guidelines for understanding
the process of reviewing manuscripts of research involving animals.
The journal will not consider any paper which is ethically unacceptable. A statement
on ethics committee permission and ethical practices must be included in all research
articles under the ‘Materials and Methods’ section. Rejection or retraction can follow
non -compliance with the ethical guidelines of the journal
Selection and Description of Participants: Describe your selection of the observational
or experimental participants (patients or laboratory animals, including controls)
clearly, including eligibility and exclusion criteria and a description of the source
Technical information: Identify the methods, apparatus (give the manufacturer’s
name and address in parentheses), and procedures in sufficient detail to allow other
workers to reproduce the results. Give references to established methods, including
Reports of randomized clinical trials should present information on all major study elements, including the protocol, assignment of interventions (methods of randomization, concealment of allocation to
treatment groups), and the method of masking (blinding), based on the CONSORT Statement (http://www.consort-statement.org).
Reporting Guidelines for Specific Study Designs
A sample size calculation based on the primary outcome with description of statistical
power is required. A power analysis should be performed before starting the study to
determine the number of subjects which need to be studied in each group to detect
a given change. Please note that a power analysis based on the primary end-point
will not necessarily be applicable to any secondary measures. It is recommended that
authors seek appropriate statistical advice before starting their study.
Statistical methods must be described with enough detail to enable a knowledgeable
reader with access to the original data to verify the report and results. It must be
described how the authors determined the clinically relevant difference to be detected
with appropriate indicators of measurement error or uncertainty (such as confidence
intervals).. Confidence intervals provide a more informative way to deal with a
significance test than a simple P value. Describe the specific tests used to examine
the primary outcome measure and also the methods for additional analyses such as
subgroup analyses and multiple comparisons. Whenever possible quantify findings and
present them with appropriate indicators of measurement error or uncertainty (such as
confidence intervals). Authors should report losses to observation (such as, dropouts
from a clinical trial). When data are summarized in the Results section, specify
the statistical methods used to analyze them. Avoid non-technical uses of technical
terms in statistics, such as ‘random’ (which implies a randomizing device), ‘normal’,
‘significant’, ‘correlations’, and ‘sample’. Define statistical terms, abbreviations, and
most symbols. Specify the computer software used. Use upper italics (P 0.048)., for
all P values include the exact value and not less than 0.05 or 0.001. Mean differences
in continuous variables, proportions in categorical variables and relative risks including
odds ratios and hazard ratios should be accompanied by their confidence intervals.
Present your results in a logical sequence in the text, tables, and illustrations, giving
the main or most important findings first. Results must be factual, stating significance
and negative findings in a logical sequence.Do not repeat in the text all the data
in the tables or illustrations; emphasize or summarize only important observations.
Extra- or supplementary materials and technical detail can be placed in an appendix where it will be accessible but will not interrupt the flow of the text; alternatively, it
can be published only in the electronic version of the journal.
When data are summarized in the Results section, give numeric results not only as derivatives (for example, percentages) but also as the absolute numbers from which the derivatives were calculated, and
specify the statistical methods used to analyze them. Restrict tables and figures to those needed to explain the argument of the paper and to assess its support. Use graphs as an alternative to tables with many entries;
do not duplicate data in graphs and tables. Where scientifically appropriate, analyses of the data by variables such as age and sex should be included.
Include summary of main findings (primary outcome measures, secondary outcome
measures, results as they relate to a prior hypothesis); then state on how they fit in
with previous studies and if they are same or different, then state reasons for the same,
ie. Interpretation and implications in the context of the totality of evidence (is there
a systematic review to refer to, if not, could one be reasonably done here and now?),
what this study adds to the available evidence, effects on patient care and health
policy, possible mechanisms; Strengths and limitations of the study (study question,
study design, data collection, analysis and interpretation); Controversies raised by this
study; Future research directions (for this particular research collaboration, underlying
mechanisms, clinical research), and conclusions based solely on the results of your study.
Do not repeat in detail data or other material given in the Introduction or the Results section. In particular, contributors should avoid making statements on economic benefits and costs unless their
manuscript includes economic data and analyses. Avoid claiming priority and alluding to work that has not been completed. New hypotheses may be stated if needed, however they should be clearly labeled as such.
About 30 references can be included. These articles generally should not have more than six authors.
Authors planning to submit review articles should first communicate with the
Editor-in-chief to ensure the appropriateness of the subject matter. It is expected
that these articles would be written by individuals who have done substantial work
on the subject or are considered experts in the field. A short summary of the work
done by the contributor(s) in the field of review should accompany the manuscript.
The prescribed word count is up to 3000 words excluding tables, references and abstract. The manuscript may have about 90 references. The manuscript should have an unstructured Abstract (250 words)
representing an accurate summary of the article. The section titles would depend upon the topic reviewed. Authors submitting review article should include a section describing the methods used for locating, selecting,
extracting, and synthesizing data. These methods should also be summarized in the abstract.
The journal expects the contributors to give post-publication updates on the subject of review. The update should be brief, covering the advances in the field after the publication of the article and should be
sent as a letter to editor, as and when major development occurs in the field.
New, interesting and rare cases can be reported. They should be unique, describing a great diagnostic or therapeutic challenge and providing a learning point for the readers. Cases with clinical significance or
implications will be given priority. These communications could be of up to 1000 words (excluding Abstract and references) and should have the following headings: Abstract (unstructured), Key-words, Introduction,
Case report, Discussion, Reference, Tables and Legends in that order.
The manuscript could be of up to 1000 words (excluding references and abstract)
and could be supported with up to 10 references. Case Reports could be authored
by up to four authors. Case reports that do not require extensive patient detail should
be submitted as correspondence.
Letter to the Editor:
These should be short and decisive observations. They should preferably be related to articles previously published in the Journal or views expressed in the journal. They should not be preliminary
observations that need a later paper for validation. The letter could have up to 500 words and 5 references. It could be generally authored by not more than four authors.
Commentaries discuss issues that are directly related to published material.
Commentaries accompany original articles, critically appraise their results and put
their conclusions into a wider context. They are typically solicited from reviewers who
provide unusually thoughtful insight during the peer review process. Commentaries
are always commissioned and should be up to 1000 words long with no more than
10 references. Commentaries do not have an abstract.
Editorials are solicited by the editorial board or Editor In Chief.
When an abbreviation first appears in the text, it must be preceded by the
complete spelling of the full term it represents, followed by the abbreviation within
parentheses. The abbreviation should be used consistently thereafter. However,
abbreviations must never be used in the Title and should be used rarely in the
Abstract. In general, avoid abbreviating terms that only appear a few times in
Units of measurement
Units should conform to the Syste`me International (SI), with the exception of units
of pressure, which should be expressed in mmHg. Diagonal slashes are acceptable
for simple units e.g., mg/kg.
Drug Names and Equipment
Use generic names. If a brand name must be used, insert it in parentheses after the
generic name. Provide manufacturer’s name, city, state, and country. Be careful
about the use of trademarked terms (e.g., ThrombelastographyTM, TEGTM, etc.).
References should be numbered consecutively in the order in which they are first mentioned in the text (not in alphabetic order). Identify references in text, tables, and legends by Arabic numerals in
superscript after the punctuation marks. References cited only in tables or figure legends should be numbered in accordance with the sequence established by the first identification in the text of the particular table or
figure. Use the style of the examples below, which are based on the formats used by the NLM in Index Medicus. The titles of journals should be abbreviated according to the style used in Index Medicus. Use complete
name of the journal for non-indexed journals. Avoid using abstracts as references. Information from manuscripts submitted but not accepted should be cited in the text as "unpublished observations" with
written permission from the source. Avoid citing a "personal communication" unless it provides essential information not available from a public source, in which case the name of the person and date of
communication should be cited in parentheses in the text.
The commonly cited types of references are shown here, for other types of references such as newspaper items please refer to ICMJE Guidelines (http://www.icmje.org
Articles in Journals
Standard journal article (for up to six authors): Shukla N, Husain N, Agarwal GG, Husain M. Utility of cysticercus fasciolaris antigen in Dot ELISA for the diagnosis of neurocysticercosis. Indian J Med Sci
Standard journal article (for more than six authors): List the first three contributors followed by et al.
Nozari Y, Hashemlu A, Hatmi ZN, Sheikhvatan M, Iravani A, Bazdar A, et al. Outcome of coronary artery bypass grafting in patients without major risk factors and patients with at least one major risk
factor for coronary artery disease. Indian J Med Sci 2007;61:547-54
Volume with supplement: Shen HM, Zhang QF. Risk assessment of nickel carcinogenicity and occupational lung cancer. Environ Health Perspect 1994; 102 Suppl 1:275-82.
Issue with supplement: Payne DK, Sullivan MD, Massie MJ. Women's psychological reactions to breast cancer. Semin Oncol 1996; 23(1, Suppl 2):89-97.
Books and Other Monographs
Personal author(s): Ringsven MK, Bond D. Gerontology and leadership skills for nurses. 2nd ed. Albany (NY): Delmar Publishers; 1996.
Editor(s), compiler(s) as author: Norman IJ, Redfern SJ, editors. Mental health care for elderly people. New York: Churchill Livingstone; 1996.
Chapter in a book: Phillips SJ, Whisnant JP. Hypertension and stroke. In: Laragh JH, Brenner BM, editors. Hypertension: pathophysiology, diagnosis, and management. 2nd ed. New York: Raven
Press; 1995. pp. 465-78.
Electronic Sources as reference
Journal article on the Internet
Abood S. Quality improvement initiative in nursing homes: the ANA acts in an advisory role. Am J Nurs [serial on the Internet]. 2002 Jun [cited 2002 Aug 12];102(6):[about 3 p.]. Available from: http://www.nursingworld.org/AJN/2002/june/Wawatch.htm
Monograph on the Internet
Foley KM, Gelband H, editors. Improving palliative care for cancer [monograph on the Internet]. Washington: National Academy Press; 2001 [cited 2002 Jul 9]. Available from: http://www.nap.edu/books/0309074029/html/.
Cancer-Pain.org [homepage on the Internet]. New York: Association of Cancer Online Resources, Inc.; c2000-01 [updated 2002 May 16; cited 2002 Jul 9]. Available from: http://www.cancer-pain.org/.
Part of a homepage/Web site
American Medical Association [homepage on the Internet]. Chicago: The Association; c1995-2002 [updated 2001 Aug 23; cited 2002 Aug 12]. AMA Office of Group Practice Liaison; [about 2 screens].
Available from: http://www.ama-assn.org/ama/pub/category/1736.html
Tables should be self-explanatory and should not duplicate textual material.
Tables with more than 10 columns and 25 rows are not acceptable.
Number tables, in Arabic numerals, consecutively in the order of their first citation in the text and supply a brief title for each.
Place explanatory matter in footnotes, not in the heading.
Explain in footnotes all non-standard abbreviations that are used in each table.
Obtain permission for all fully borrowed, adapted, and modified tables and provide a credit line in the footnote.
For footnotes use the following symbols, in this sequence: *, †, ‡, §, ||,¶ , **, ††, ‡‡
Tables with their legends should be provided at the end of the text after the references. The tables along with their number should be cited at the relevant place in the text
Upload the images in JPEG format. The file size should be within 4 MB in size while uploading.
Figures should be numbered consecutively according to the order in which they have been first cited in the text.
Labels, numbers, and symbols should be clear and of uniform size. The lettering for figures should be large enough to be legible after reduction to fit the width of a printed column.
Symbols, arrows, or letters used in photomicrographs should contrast with the background and should be marked neatly with transfer type or by tissue overlay and not by pen.
Titles and detailed explanations belong in the legends for illustrations not on the illustrations themselves.
When graphs, scatter-grams or histograms are submitted the numerical data on which they are based should also be supplied.
The photographs and figures should be trimmed to remove all the unwanted areas.
If photographs of individuals are used, their pictures must be accompanied by written permission to use the photograph.
If a figure has been published elsewhere, acknowledge the original source and submit written permission from the copyright holder to reproduce the material. A credit line should appear in the
legend for such figures.
Legends for illustrations: Type or print out legends (maximum 40 words, excluding the credit line) for illustrations using double spacing, with Arabic numerals corresponding to the illustrations.
When symbols, arrows, numbers, or letters are used to identify parts of the illustrations, identify and explain each one in the legend. Explain the internal scale (magnification) and identify the method of staining in
Final figures for print production: If the uploaded images are not printable quality, the publishing office may request for higher resolution images which can be sent at the time of accptance of the
manuscript. Send sharp, glossy, un-mounted, color photographic prints, with height of 4 inches and width of 6 inches at the time of submitting the revised manuscript. Print outs of digital photographs are not
acceptable. If digital images are the only source of images, ensure that the image has minimum resolution of 300 dpi or 1800 x 1600 pixels in TIFF format. Send the images on a CD. Each figure should have a label pasted
(avoid use of liquid gum for pasting) on its back indicating the number of the figure, the running title, top of the figure and the legends of the figure. Do not write the contributor/s' name/s. Do not write on the
back of figures, scratch, or mark them by using paper clips.
The Journal reserves the right to crop, rotate, reduce, or enlarge the photographs to an acceptable size.
Protection of Patients' Rights to Privacy
Identifying information should not be published in written descriptions, photographs,
sonograms, CT scans, etc., and pedigrees unless the information is essential for
scientific purposes and the patient (or parent or guardian, wherever applicable) gives
written informed consent for publication. Authors should remove patients’ names
from figures unless they have obtained written informed consent from the patients.
When informed consent has been obtained, it should be indicated in the article and
copy of the consent should be attached with the covering letter. Please collect and
keep copies of patients’ consent forms on which patients or other subjects of your
experiments clearly grant permission for the publication of photographs or other
material that might identify them. A statement to the effect that such consent had
been obtained must be included in the ‘Methods’ section of your paper. If necessary
the Editors may request a copy of any consent forms.
The Journal is a member of the Committee on Publications Ethics (COPE) and
adheres to COPE’s Good Publication Practice (see http://publicationethics.org).
There are a number of types of academic misconduct, for which we draw special
attention to the following: plagiarism, duplicate publication, and data
falsification. Plagiarism is the use of previously published material without
attribution. Manuscripts that plagiarize previously published material, even if it is
the author’s own work, will be rejected if identified during peer review and will be
retracted if the plagiarism is discovered after publication. Duplicate publication is
publication of a manuscript with considerable content overlap with a prior article
by the same author or coauthors and is strongly discouraged by the journal. Prior
publication of an abstract does not count as duplicate publication. We request
that authors inform the Journal when parts of a manuscript have previously been
published as an abstract. Duplicate submission is concurrent submission of a nearly
identical manuscript to 2 journals. Duplicate submissions identified during peer
review will be immediately rejected. Duplicate submissions that are discovered
after publication will be retracted. Data falsification is any manipulation of data
that is not disclosed in the publication. This can include editing data (removing
outliers, altering values), creating false data, or misrepresenting data analysis
(e.g., describing an intent-to-treat analysis but actually performing a per-protocol
analysis). Any manuscript in which the data have been falsified will be rejected
if the falsification is discovered during peer review. If the manuscript has been
published, it will be retracted. The journal office reserves the right to request for
any raw data pertaining to the study for additional verification if any discrepancy
is reported at any time.
Sending a revised manuscript
The revised version of the manuscript should be submitted online in a manner similar
to that used for submission of the manuscript for the first time. However, there is
no need to submit the “First Page” or “Covering Letter” file while submitting a
revised version. When submitting a revised manuscript, contributors are requested to
include, the ‘referees’ remarks along with point to point clarification at the beginning
in the revised file itself (the reply template may be downloaded from the website). In
addition, they are expected to mark the changes as underlined or colored text in the
article. Authors should refrain in making personal remarks and should address any
grievances regarding appropriateness of review process directly to the Chief Editor.
Reprints and proofs
Journal provides no free printed reprints. Authors can purchase reprints, payment for which should be done at the time of submitting the proofs.
Proofs will be sent to the corresponding authors by email approximately 2 weeks before the publication date. The issues are published in last week of the previous month.
Manuscript submission, processing and publication charges
Journal does not charge the authors or authors’ institutions for the submission, processing and/or publications of manuscripts.
The entire contents of the Journal of Anaesthesiology Clinical Pharmacology are protected under Indian and international copyrights. The Journal, however, grants to all users a free, irrevocable, worldwide,
perpetual right of access to, and a license to copy, use, distribute, perform and display the work publicly and to make and distribute derivative works in any digital medium for any reasonable non-commercial purpose,
subject to proper attribution of authorship and ownership of the rights. The journal also grants the right to make small numbers of printed copies for their personal non-commercial use under Creative Commons
Attribution-Noncommercial-Share Alike 3.0 Unported License.
Authors who may have a complaint against any of the aspects of their communication
or dealings with the Journal of Anaesthesiology Clinical Pharmacology should,
in the first instance, write an e-mail to the Editor responsible for handling the
manuscript. In case it does not resolve the issue, the complaint should be forwarded
to the Editor-in-Chief. The Editors and Editor-in-Chief aim to acknowledge and
redress the complaint jointly within 10 days of receiving it.
Signed by all contributors
Previous publication / presentations mentioned
Source of funding mentioned
Conflicts of interest disclosed
- Ethics committee approval number and Trial Registry ID and dates.
Last name and given name provided along with Middle name initials (where applicable)
Author for correspondence, with e-mail address provided
Number of contributors restricted as per the instructions
Identity not revealed in paper except title page (e.g. name of the institute in Methods, citing previous study as 'our study', names on figure labels, name of institute in photographs, etc.)
Presentation and format
Margins 2.5 cm from all four sides
Page numbers included at bottom
Title page contains all the desired information
Running title provided (not more than 50 characters)
Abstract page contains the full title of the manuscript
Abstract provided (structured abstract of 250 words for original articles, unstructured abstracts of about 150 words for all other manuscripts excluding letters to the Editor)
Key words provided (three or more)
Introduction of 75-100 words
Headings in title case (not ALL CAPITALS)
The references cited in the text should be after punctuation marks, in superscript with square bracket.
References according to the journal's instructions, punctuation marks checked
Send the article file without ‘Track Changes’
Language and grammar
Uniformly American English
Write the full term for each abbreviation at its first use in the title, abstract, keywords and text separately unless it is a standard unit of measure. Numerals from 1 to 10 spelt out
Numerals at the beginning of the sentence spelt out
Check the manuscript for spelling, grammar and punctuation errors
If a brand name is cited, supply the manufacturer's name and address (city and state/country).
Species names should be in italics
Tables and figures
No repetition of data in tables and graphs and in text
Actual numbers from which graphs drawn, provided
Figures necessary and of good quality (colour)
Table and figure numbers in Arabic letters (not Roman)
Labels pasted on back of the photographs (no names written)
Figure legends provided (not more than 40 words)
Patients' privacy maintained (if not permission taken)
Credit note for borrowed figures/tables provided
Write the full term for each abbreviation used in the table as a footnote
(to be modified as applicable and one signed copy attached with the manuscript)
I/we certify that I/we have participated sufficiently in contributing to the intellectual content, concept and design of this work or the analysis and interpretation of the data (when applicable), as well as
writing of the manuscript, to take public responsibility for it and have agreed to have my/our name listed as a contributor.
I/we believe that the manuscript represents valid work. Neither this manuscript nor one with substantially similar content under my/our authorship has been published or is being considered for
publication elsewhere, except as described in the covering letter. I/we certify that all the data collected during the study is presented in this manuscript and no data from the study has been or will be published
separately. I/we attest that, if requested by the editors, I/we will provide the data/information or will cooperate fully in obtaining and providing the data/information on which the manuscript is based, for examination
by the editors or their assignees. Financial interests, direct or indirect, that exist or may be perceived to exist for individual contributors in connection with the content of this paper have been disclosed in the cover
letter. Sources of outside support of the project are named in the covering letter.
I/We hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership, including any and all rights incidental thereto, exclusively to the Journal of Anaesthesiology Clinical Pharmacology, in the
event that such work is published by the Journal of Anaesthesiology Clinical Pharmacology. The Journal of Anaesthesiology Clinical Pharmacology shall own the work, including
the right to grant permission to republish the article in whole or in part, with or without fee;
the right to produce preprints or reprints and translate intouages other than English for sale or free distribution; and
the right to republish the work in a collection of articles in any other mechanical or electronic format.
We give the rights to the corresponding author to make necessary changes as per the request of the journal, do the rest of the correspondence on our behalf and he/she will act as the guarantor for the
manuscript on our behalf.
All persons who have made substantial contributions to the work reported in the manuscript, but who are not contributors, are named in the Acknowledgment and have given me/us their written permission
to be named. If I/we do not include an Acknowledgment that means I/we have not received substantial contributions from non-contributors and no contributor has been omitted.
Name Signature Date signed
1 --------------- --------------- ---------------
2 --------------- --------------- ---------------
3 --------------- --------------- ---------------
4 --------------- --------------- --------------- (up to 4 contributors for case report/ images/ review)
5 --------------- --------------- ---------------
6 --------------- --------------- --------------- (up to 6 contributors for original studies)
Click here to download instructions
Click here to download copyright form
These ready to use templates are made to help the contributors write as per the requirements of the Journal.
Save the templates on your computer and use them with a word processor program.
Click open the file and save as the manuscript file.
In the program keep 'Document Map' and 'Comments' on from 'View' menu to navigate through the file.
Download Template for Original Articles/ABSTRACT Reports. (.DOT file)
Download Template for Case Reports. (.DOT file)
Download Template for Review Articles. (.DOT file)
Download Template for Letter to the Editor. (.DOT file)